Royce & Associates LP V Tv Therapeutics Inc. Transaction History

Royce & Associates LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 09, 2018	SELL	$0.71 - $4.04 $257,730 - $1.47 Million	-363,000 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$3.91 - $7.83 $539,580 - $1.08 Million	138,000 Added 61.33%	363,000 $1.48 Million
Q4 2017 Feb 09, 2018	BUY	$3.9 - $7.77 $877,500 - $1.75 Million	225,000	225,000 $1.35 Million

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.59B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.